Investors with the goal of beating the broader market often turn to stock selection. Strategic choices in individual stocks can have a profound impact on your wealth.
In the latest session, Qiagen NV (NYSE: QGEN) closed at $46.82 down -0.26% from its previous closing price of $46.94. In other words, the price has decreased by -$0.26 from its previous closing price. On the day, 1.33 million shares were traded. QGEN stock price reached its highest trading level at $46.92 during the session, while it also had its lowest trading level at $46.4.
Ratios:
For a deeper understanding of Qiagen NV’s stock, let’s take a closer look at its various ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 6.01 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 21.20. For the most recent quarter (mrq), Quick Ratio is recorded 2.30 and its Current Ratio is at 2.60. In the meantime, Its Debt-to-Equity ratio is 0.58 whereas as Long-Term Debt/Eq ratio is at 0.45.
Upgrades & Downgrades
In the most recent recommendation for this company, Barclays on June 24, 2025, initiated with a Overweight rating and assigned the stock a target price of $55.
Robert W. Baird Downgraded its Outperform to Neutral on February 19, 2025, whereas the target price for the stock was revised from $52 to $42.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Aug 15 ’25 when Thierry Bernard bought 25,000 shares for $48.80 per share.
ROLAND SACKERS bought 31,423 shares of QGEN for $1,546,257 on Aug 15 ’25. On Aug 14 ’25, another insider, ROLAND SACKERS, who serves as the Officer of the company, bought 18,577 shares for $49.00 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, QGEN now has a Market Capitalization of 10152495104 and an Enterprise Value of 10618795008. As of this moment, Qiagen’s Price-to-Earnings (P/E) ratio for their current fiscal year is 25.26, and their Forward P/E ratio for the next fiscal year is 18.61. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 3.52. For the stock, the TTM Price-to-Sale (P/S) ratio is 4.90 while its Price-to-Book (P/B) ratio in mrq is 2.78. Its current Enterprise Value per Revenue stands at 5.128 whereas that against EBITDA is 10.437.
Stock Price History:
The Beta on a monthly basis for QGEN is 0.66, which has changed by 0.080819726 over the last 52 weeks, in comparison to a change of 0.12415576 over the same period for the S&P500. Over the past 52 weeks, QGEN has reached a high of $51.88, while it has fallen to a 52-week low of $37.63. The 50-Day Moving Average of the stock is 1.10%, while the 200-Day Moving Average is calculated to be 4.12%.
Shares Statistics:
For the past three months, QGEN has traded an average of 1.15M shares per day and 1082760 over the past ten days. A total of 216.84M shares are outstanding, with a floating share count of 215.78M. Insiders hold about 0.49% of the company’s shares, while institutions hold 76.23% stake in the company. Shares short for QGEN as of 1763078400 were 6164497 with a Short Ratio of 5.36, compared to 1760486400 on 6005547. Therefore, it implies a Short% of Shares Outstanding of 6164497 and a Short% of Float of 4.22.
Dividends & Splits
According to the company, the forward annual dividend rate for QGEN is 0.25, from 0.25 in the trailing year. Against a Trailing Annual Dividend Yield of 0.0053259484. The current Payout Ratio is 0.00% for QGEN, which recently paid a dividend on 2025-07-02 with an ex-dividend date of 2025-07-02. Stock splits for the company last occurred on 2017-01-25 when the company split stock in a 962:1000 ratio.
Earnings Estimates
The stock of Qiagen NV (QGEN) is currently in the spotlight, with 11.0 analysts actively rating and assessing its market standing.The consensus estimate for the next quarter is $0.58, with high estimates of $0.6 and low estimates of $0.55.
Analysts are recommending an EPS of between $2.76 and $2.35 for the fiscal current year, implying an average EPS of $2.39. EPS for the following year is $2.54, with 16.0 analysts recommending between $2.96 and $2.41.
Revenue Estimates
A total of 10 analysts believe the company’s revenue will be $528.8M this quarter.It ranges from a high estimate of $532.06M to a low estimate of $527M. As of. The current estimate, Qiagen NV’s year-ago sales were $521.2MFor the next quarter, 10 analysts are estimating revenue of $510.39M. There is a high estimate of $517.2M for the next quarter, whereas the lowest estimate is $499M.
A total of 17 analysts have provided revenue estimates for QGEN’s current fiscal year. The highest revenue estimate was $2.1B, while the lowest revenue estimate was $2.04B, resulting in an average revenue estimate of $2.08B. In the same quarter a year ago, actual revenue was $1.98BBased on 17 analysts’ estimates, the company’s revenue will be $2.2B in the next fiscal year. The high estimate is $2.25B and the low estimate is $2.16B.
